The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease

Current Diabetes Reports

Volumn 10, Issue 1, 2010, Pages 37-42

  Chaudhary, Kunal ^a   Phadke, Gautam ^a   Nistala, Ravi ^a   Weidmeyer, Charles E ^a   McFarlane, Samy I ^a   Whaley Connell, Adam ^a  

^a University of Missouri   (United States)

Author keywords

ADMA; KIM 1; NGAL; TGF

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN C; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LIVER TYPE FATTY ACID BINDING PROTEIN; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NEPHRIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PODOCIN; SYNAPTOPODIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; MICROALBUMINURIA; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; UREA BLOOD LEVEL;

ALBUMINURIA; ANIMALS; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC;

EID: 77249168659     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0080-z     Document Type: Review

References (53)

1. S Adler 2004 Diabetic nephropathy: linking histology, cell biology, and genetics Kidney Int 66 2095 2106 10.1111/j.1523-1755.2004.00988.x 15496194
2. V Thongboonkerd P Malasit 2005 Renal and urinary proteomics: current applications and challenges Proteomics 5 1033 1042 10.1002/pmic.200401012 1:CAS:528:DC%2BD2MXivVGgt7o%3D 15669002 (Pubitemid 40469033)
3. US Renal Data System: Annual Report of the US Renal Data System 2007. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
4. J Coresh E Selvin LA Stevens, et al. 2007 Prevalence of chronic kidney disease in the United States JAMA 298 2038 2047 10.1001/jama.298.17.2038 1:CAS:528:DC%2BD2sXht1yjsLnM 17986697 (Pubitemid 350074801)
5. JP Bosch 1995 Renal reserve: a functional view of glomerular filtration rate Semin Nephrol 15 381 385 1:STN:280:DyaK28%2FptVOjsw%3D%3D 8525139
6. J Herrera B Rodríguez-Iturbe 1998 Stimulation of tubular secretion of creatinine in health and in conditions associated with reduced nephron mass. Evidence for a tubular functional reserve Nephrol Dial Transplant 13 623 629 10.1093/ndt/13.3.623 1:CAS:528:DyaK1cXit1OqtL4%3D 9550637 (Pubitemid 28119042)
7. YS Kanwar ZZ Liu N Kashihara EI Wallner 1991 Current status of the structural and functional basis of glomerular filtration and proteinuria Semin Nephrol 11 390 413 1:STN:280:DyaK38%2FltlGqtA%3D%3D 1947494
8. A Guasch WM Deen BD Myers 1993 Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans J Clin Invest 92 2274 2282 10.1172/JCI116831 1:CAS:528:DyaK2cXltFOmsg%3D%3D 8227342 (Pubitemid 23333533)
9. JC Peterson S Adler JM Burkart, et al. 1995 Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 754 762 1:STN:280:DyaK28%2FjtVOntw%3D%3D 7574193
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) [no authors listed]. Lancet 1997, 349:1857-1863.
11. G Remuzzi P Ruggenenti A Benigni 1997 Understanding the nature of renal disease progression Kidney Int 51 2 15 10.1038/ki.1997.2 1:STN:280: DyaK2s7kvVyrtQ%3D%3D 8995712 (Pubitemid 27064516)
12. JT Wright Jr G Bakris T Greene, et al. 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. African American Study of Kidney Disease and Hypertension Study Group JAMA 288 2421 2431 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D 12435255 (Pubitemid 35340538)
13. P Rossing 2005 The changing epidemiology of diabetic microangiopathy in type I diabetes Diabetologia 48 1439 1444 10.1007/s00125-005-1836-x 1:STN:280:DC%2BD2MvivFGgsQ%3D%3D 15986235 (Pubitemid 41175492)
14. RD Toto 2004 Microalbuminuria: definition, detection, and clinical significance J Clin Hypertens (Greenwich) 6 11 Suppl 3 2 7 10.1111/j.1524-6175. 2004.4064.x 1:CAS:528:DC%2BD2cXhtVChsrvK
15. N Bank 1991 Mechanisms of diabetic hyperfiltration Kidney Int 40 792 807 10.1038/ki.1991.277 1:STN:280:DyaK38%2FnvFClsw%3D%3D 1745032
16. G Ding K Reddy AA Kapasi, et al. 2002 Angiotensin II induces apoptosis in rat glomerular epithelial cells Am J Physiol Renal Physiol 283 F173 F180 1:CAS:528:DC%2BD38XlsVCkurw%3D 12060599
17. ME Pagtalunan PL Miller S Jumping-Eagle, et al. 1997 Podocyte loss and progressive glomerular injury in type II diabetes J Clin Invest 99 342 348 10.1172/JCI119163 1:CAS:528:DyaK2sXntV2rtA%3D%3D 9006003
18. TW Meyer PH Bennett RG Nelson 1999 Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria Diabetologia 42 1341 1344 10.1007/s001250051447 1:CAS:528:DyaK1MXmvF2ms7c%3D 10550418 (Pubitemid 29500971)
19. RM Mason NA Wahab 2003 Extracellular matrix metabolism in diabetic nephropathy J Am Soc Nephrol 14 1358 1373 10.1097/01.ASN.0000065640.77499.D7 1:CAS:528:DC%2BD3sXislKjtbw%3D 12707406 (Pubitemid 36519197)
20. KS Eardley D Zehnder M Quinkler, et al. 2006 The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease Kidney Int 69 1189 1197 10.1038/sj.ki.5000212 1:CAS:528:DC%2BD28XivFOmsbc%3D 16609683
21. AC Ong LG Fine 1994 Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int 45 345 351 10.1038/ki.1994.44 1:STN:280:DyaK2c3hslemsg%3D%3D 8164418
22. KA Nath 1992 Tubulointerstitial changes as a major determinant in the progression of renal damage Am J Kidney Dis 20 1 17 1:STN:280: DyaK38zitFWjtA%3D%3D 1621674
23. •• Crowley SD, Vasievich MP, Ruiz P, et al.: Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953. This is a seminal paper that outlined the importance of the kidney and the RAS in regulating blood pressure.
24. C Aros G Remuzzi 2002 The renin-angiotensin system in progression, remission and regression of chronic nephropathies J Hypertension Suppl 20 S45 S53 10.1097/00004872-200201000-00008 1:CAS:528:DC%2BD38Xlt1Kmsbo%3D (Pubitemid 34913401)
25. S Schaub J Wilkins T Weiler, et al. 2004 Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry Kidney Int 65 323 332 10.1111/j.1523-1755.2004.00352.x 1:CAS:528: DC%2BD2cXmt1Whsw%3D%3D 14675066 (Pubitemid 38037520)
26. P Vestergaard R Leverett 1958 Constancy of urine creatinine excretion J Lab Clin Med 51 211 218 1:CAS:528:DyaG1cXjs1aktg%3D%3D 13514226
27. E Schiffer H Mischak J Novak 2006 High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS Proteomics 6 5615 5627 10.1002/pmic.200600230 1:CAS:528:DC%2BD28XhtFyms7fP 16991199 (Pubitemid 44683225)
28. K Mori HT Lee D Rapoport, et al. 2005 Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury J Clin Invest 115 610 621 1:CAS:528:DC%2BD2MXit1emsbc%3D 15711640
29. CR Parikh A Jani VY Melnikov, et al. 2004 Urinary interleukin-18 is a marker of human acute tubular necrosis Am J Kidney Dis 43 405 414 10.1053/j.ajkd.2003.10.040 1:CAS:528:DC%2BD2cXislaqsrg%3D 14981598 (Pubitemid 38298199)
30. TL Nickolas MJ O'Rourke J Yang, et al. 2008 Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury Ann Intern Med 148 810 819 18519927
31. K Miyauchi Y Takiyama J Honjyo, et al. 2009 Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells Diabetes Res Clin Pract 83 190 199 10.1016/j.diabres.2008.11.018 1:CAS:528:DC%2BD1MXhtVCqurs%3D 19110334
32. Hall IE, Yarlagadda SG, Coca SG, et al.: IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2009 Sep 17 (Epub ahead of print).
33. J Malyszko JS Malyszko H Bachorzewska-Gajewska, et al. 2009 Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients Transplant Proc 41 158 161 10.1016/j.transproceed.2008.10.088 1:CAS:528: DC%2BD1MXisVOnsro%3D 19249502
34. D Bolignano A Lacquaniti G Coppolino, et al. 2009 Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease Clin J Am Soc Nephrol 4 337 344 10.2215/CJN.03530708 1:CAS:528: DC%2BD1MXjslagtbc%3D 19176795
35. K Mori K Nakao 2007 Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage Kidney Int 71 967 970 10.1038/sj.ki.5002165 1:CAS:528:DC%2BD2sXltVKjsrc%3D 17342180 (Pubitemid 46741985)
36. T Ichimura JV Bonventre V Bailly, et al. 1998 Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury J Biol Chem 273 4135 4142 10.1074/jbc.273.7.4135 1:CAS:528:DyaK1cXht1ahsLg%3D 9461608 (Pubitemid 28103282)
37. WK Han V Bailly R Abichandani, et al. 2002 Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury Kidney Int 62 237 244 10.1046/j.1523-1755.2002.00433.x 1:CAS:528:DC%2BD38XlsFyqurc%3D 12081583 (Pubitemid 34754067)
38. F Waanders VS Vaidya H van Goor, et al. 2009 Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial Am J Kidney Dis 53 16 25 10.1053/j.ajkd.2008.07.021 1:CAS:528: DC%2BD1MXhslyrtbk%3D 18823687
39. ML Merchant BA Perkins GM Boratyn, et al. 2009 Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria J Am Soc Nephrol 20 2065 2074 10.1681/ASN.2008121233 1:CAS:528:DC%2BD1MXhtFKqu7rF 19643930
40. MA Brehm TM Schenk X Zhou, et al. 2007 Intracellular localization of human Ins(1, 3, 4, 5, 6)P5 2-kinase Biochem J 408 335 345 10.1042/BJ20070382 1:CAS:528:DC%2BD2sXhtlGmtbnN 17705785
41. W Kriz N Gretz KV Lemley 1998 Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54 687 697 10.1046/j.1523-1755.1998.00044.x 1:STN:280:DyaK1cvgtlKlsQ%3D%3D 9734594 (Pubitemid 28397387)
42. W Kriz 2002 Podocyte is the major culprit accounting for the progression of chronic renal disease Microsc Res Tech 57 189 195 10.1002/jemt.10072 12012382 (Pubitemid 34553247)
43. M Hara T Yanagihara M Itoh, et al. 1998 Immunohistochemical and urinary markers of podocyte injury Pediatr Nephrol 12 43 48 10.1007/s004670050401 1:STN:280:DyaK1c7mtFKksQ%3D%3D 9502567 (Pubitemid 28165780)
44. T Nakamura C Ushiyama S Suzuki, et al. 2000 Urinary excretion of podocytes in patients with diabetic nephropathy Nephrol Dial Transplant 15 1379 1383 10.1093/ndt/15.9.1379 1:STN:280:DC%2BD3M%2Fhs1Gisg%3D%3D 10978394
45. CC Szeto KB Lai KM Chow, et al. 2005 Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases Clin Chim Acta 361 182 190 10.1016/j.cccn.2005.05.016 1:CAS:528:DC%2BD2MXhtVGrsLbN 15996647 (Pubitemid 41382622)
46. Y Sato BL Wharram SK Lee, et al. 2009 Urine podocyte mRNAs mark progression of renal disease J Am Soc Nephrol 20 1041 1052 10.1681/ASN. 2007121328 1:CAS:528:DC%2BD1MXlvFKqtrk%3D 19389856
47. D Yu A Petermann U Kunter, et al. 2005 Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria J Am Soc Nephrol 16 1733 1741 10.1681/ASN.2005020159 1:CAS:528:DC%2BD2MXls1eiu7c%3D 15829708 (Pubitemid 41716479)
48. G Wang FM Lai BC Kwan, et al. 2009 Podocyte loss in human hypertensive nephrosclerosis Am J Hypertens 22 300 306 10.1038/ajh.2008.360 19131934
49. CC Szeto RW Chan KB Lai, et al. 2005 Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases Nephrol Dial Transplant 20 105 113 10.1093/ndt/gfh574 1:CAS:528:DC%2BD2MXisValtA%3D%3D 15561743 (Pubitemid 40207614)
50. C Zoccali S Bode-Boger F Mallamaci, et al. 2001 Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study Lancet 358 2113 2117 10.1016/S0140-6736(01)07217-8 1:CAS:528:DC%2BD38XitV2gsQ%3D%3D 11784625 (Pubitemid 34094901)
51. D Fliser F Kronenberg JT Kielstein, et al. 2005 Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study J Am Soc Nephrol 16 2456 2461 10.1681/ASN.2005020179 1:CAS:528:DC%2BD2MXovVOku7Y%3D 15930091 (Pubitemid 41725064)
52. K Nakamura K Ito Y Kato, et al. 2008 L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules Drug Metab Pharmacokinet 23 271 278 10.2133/dmpk.23.271 1:CAS:528:DC%2BD1cXht12itLrP 18762714
53. K Negishi E Noiri K Doi, et al. 2009 Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury Am J Pathol 174 1154 1159 10.2353/ajpath.2009.080644 1:CAS:528:DC%2BD1MXksVOksb4%3D 19264903